PopUp Close
Added to notepad
PopUp Close
Added to notepad
PopUp Close
Vielen Dank!
Ihre Nachricht wurde erfolgreich an uns versendet - wir melden uns bei Ihnen!
Currently there are no tools on your notepad
You have questions about our tools?

    * Mandatory field

    There are currently no Impuls-Sessions on your notepad
    Request desired appointment

      * Mandatory field


      Industry experts on board

      Former product and business managers from major pharma players in the Exevia team.

      International capability

      International team members and trusted industry partners covering healthcare systems worldwide.

      Broad indication area experience

      From familial hypercholesterolemia and solid tumours to OTC supplements and decongestants – there is little we have not researched.

      Target group access

      We work with specialist healthcare recruiters to reach general physicians, specialists, pharmacists, patients, payers, healthcare administrators, and KOLs.

      Example of questions we investigate

      The example below gives you an idea of a study we have conducted. Viel lieber aber würden wir Ihnen persönlich zeigen, was wir können.
      Talk to us, ask us your questions, and learn more about our expertise in your industry.

      Breast Cancer Patient Preferences

      Pharma - The business issue

      In Germany, reimbursable drugs are subject to an assessment by the Institute for Quality and Efficiency in Health Care (IQWiG). Our client was preparing a benefit assessment of a new oncology drug for breast cancer which was to include findings on patients’ preferences. Conjoint studies, in particular, are accepted as a valid approach to identify such preferences by IQWiG.

      Pharma - Our solution

      Through preliminary studies – including desk research as well as qualitative interviews with patients and HCPs – a comprehensive understanding of the indication, the views, language and needs of the breast cancer patients was generated. The conjoint study was built upon insights from preliminary research and validated in an extensive pre-test phase before launching. Each step in the research process, analysis and data collection with a robust sample was documented and justified in detail to ensure acceptance by IQWiG’s reviewers.

      Pharma - Our impact

      The patient preference study enabled our client to enrich their benefit dossier for IQWiG with a further line of argumentation and substantiate the product’s benefit from the patient perspective. In addition, our client was able to publish the research in relevant scientific journals and generate further product benefit awareness.

      Your Contact
      Psyma Contact
      Roland Herterich
      Managing Director
      Psyma+Exevia Health GmbH
      DE Rückersdorf / Nürnberg